ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cobimetinib

Also written as “Cobimetinib”, “HM95573, cobimetinib” and “GDC-0973 IV Infusion”.

Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Neoplasms · Ovarian Neoplasms, led by 2 companies.

Drug pageCobimetinib: every studyAll 94 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 18, 201238 company-led studies, 6 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only364 open or runningphase 3since Sep 18, 2012Apr 18, 2007Nov 30, 2026phase 2 · NCT04302025
Hanmi Pharmaceutical22 open or runningphase 2since Feb 27, 2026Aug 7, 2017Sep 2029phase 2 · NCT07449754

Also a collaborator on its studies: Halozyme Therapeutics and BioLineRx.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hanmi Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2017First study: phase 1 study in Neoplasm MetastasisFirst studyNCT03284502 · 148 enrolled · Korea, Republic of
  2. Feb 27, 2026Phase 2 study in MelanomaPhase 2 reachedNCT07449754 · 45 planned · South Korea

Ahead

  1. Sep 2029Primary completion: phase 2 study in MelanomaNCT07449754

TargetBeta

“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
pimasertibruleMerck KGaA, Darmstadt, Germanyphase 213
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 29
polfurmetinibPfizerphase 13

Studies

All 2 Hanmi Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07449754Melanoma · South Korea2RecruitingSep 202945
NCT03284502Neoplasm Metastasis · Korea, Republic of1Active, not recruitingSep 30, 2024148

How it is read

Names in the registry

  • “Cobimetinib”, 34 entries
  • “cobimetinib”, 4 entries
  • “HM95573, cobimetinib”, 2 entries
  • “GDC-0973 IV Infusion”, 1 entry
  • “GDC-0973 Oral Capsules”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.